The first reported case of trastuzumab induced interstitial lung disease associated with anti-neutrophil cytoplasmic antibody vasculitis – A case report and a prospective cohort study on the usefulness of neutrophil derived biomarkers in monitoring vasculitis disease activity during follow-up

Chen-Han Chang a,**, 1, Chiau-Jing Jung b, Yi-Ming Huang c, Lo Chiao d, Yih-Leong Chang e, f, Song-Chou Hsieh g, Ching-Hung Lin a, h, Yu-Min Kuo i, *, 1

a Department of Medical Oncology, National Taiwan University Hospital, Taipei, Taiwan
b Department of Microbiology and Immunology, School of Medicine, Taipei Medical University, Taipei, Taiwan
c Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan
d Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan
e Graduate Institute of Pathology, College of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan
f Department of Pathology, National Taiwan University Cancer Center and National Taiwan University College of Medicine, Taipei, Taiwan
g Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
h Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
i Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan

1 These authors contributed equally to this work.

Article info
Article history:
Received 20 June 2021
Received in revised form
15 November 2021
Accepted 23 November 2021
Available online 29 November 2021

Keywords:
Trastuzumab
Antineutrophil cytoplasmic antibody
Interstitial lung disease
Breast cancer

Abstract
Targeted therapies against human epidermal growth factor receptor 2 (HER2) are associated with increased interstitial lung disease (ILD). Trastuzumab, lapatinib, pertuzumab, and trastuzumab emtansine have markedly extended HER2 breast cancer survival but current knowledge on how these HER2-targeted agents induce interstitial lung disease is still poorly defined due to limited cases in the literature. Physicians mostly managed this complication by dose interruption, dose de-escalation, or discontinuation with success. In 2019, the FDA had granted accelerated approval on trastuzumab deruxtecan (T-Dxd) in HER2 breast cancer in the late line setting. Severe ILD incidence rate was over ten percent and led to fatal outcomes in 2.2% of patients in the T-Dxd trial. Searching for biomarkers to detect ILD incidence before it becomes clinically fulminant or for treatment response monitoring is of high clinical value.

A Case of life-threatening trastuzumab-induced ILD was encountered in our facility. The ILD was confirmed to be antineutrophil cytoplasmic antibody (ANCA) pulmonary capillaritis. The biomarker of neutrophil extracellular traps (NETs), serum MPO-DNA complex, showed a good correlation with the clinical severity. Soon after B cell depleting agent rituximab usage, the serum MPO-DNA outperformed ANCA autoantibody and maintained its correlation with clinical severity. In addition to the trastuzumab-induced ILD case, a prospective cohort in our facility also confirmed the usefulness of MPO-DNA in monitoring vasculitis activity. We postulated that upfront testing with biomarkers of vasculitis during HER2 targeted treatment with high ILD incidence may be beneficial in the future.

© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
The HER-2 gene is a poor prognostic factor in breast cancer and is amplified in 20–25% of patients [1]. Trastuzumab is a humanized monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2). Since its first approval in 1998, subsequently developed HER2 agents such as
lapatinib, pertuzumab, and trastuzumab emtansine have markedly extended the HER2 breast cancer patient survival [2–4].

Drug-induced interstitial lung disease (DIILD) accounts for 3–5% of interstitial lung disease. Cancer therapy is the leading cause of DIILD and accounts for 23–51% of the cases [5]. Although the incidence of trastuzumab-related ILD in the registration trials was low at 0.5%, the mortality rate with treatment-related ILD was around 20% [6–8]. In 2019 the novel HER-2 antibody-drug conjugate trastuzumab deruxtecan (T-Dxd) had recently drawn attention for leukocytosis (WBC 11.01 k/μL, neutrophil 74.2%, lymphocyte 17.6%, eosinophil 2.5%), anemia and thrombocytopenia (hemoglobin 9.8 g/dL, platelet 126 k/μL). The coagulation profile, as well as liver and kidney biochemistry, were within normal limits. She was admitted for empirical community-acquired pneumonia treatment with ceftriaxone and azithromycin. However, on the third day, the patient was febrile and developed respiratory distress, requiring oxygen mask support. A chest CT with contrast showed diffuse ground-glass opacities, consistent with non-infectious pneumonitis. Tests for empirical community-acquired pneumonia treatment with ceftriaxone and azithromycin were performed for empirical community-acquired pneumonia treatment with ceftriaxone and azithromycin, but negative results. Cultures for blood and sputum were also negative. Non-infectious pneumonitis was suspected, and a connective tissue disease survey was conducted. However, hypoxic respiratory failure progressed, and the patient was intubated on the seventh day. The patient was extubated after 14 days of ventilator support.

Trastuzumab-related ANCA capillaritis was diagnosed after reviewing the patient’s history. She had no pulmonary symptoms or chest X-ray abnormality in previous health check-ups. The Naranjo algorithm, an adverse drug reaction (ADE) assessment tool having a scale of 1–10 [10], was applied with trastuzumab scoring 7 out of 10 (Table 1). Probable trastuzumab-related ADE was suspected. Considering this ADE as a life-threatening event, the trastuzumab schedule was permanently discontinued and replaced with hormonal adjuvant therapy. She also received rheumatologist follow up since this event at the outpatient clinic.

1.2. Utilization of different vasculitis markers in the trastuzumab ILD case

Systemic methylprednisolone had induced rapid remission of the chest X-ray infiltration and inflammatory marker (e.g. C-reactive protein, erythrocyte sedimentation rate, D-dimer) improvement during the initial induction period (Table 2). However, the patient still manifested with residual vasculitis disease activity of leg weakness, numbness, and also persistent microscopic hematuria and proteinuria. Occasional expectoration of blood clot content was also noted despite no evident change in the chest X-ray appearance. The measurement of Birmingham Vasculitis Activity Score (BVAS) [11], a tool of vasculitis activity measurement consisted of 9 organs, and a score of 0–33 for persistent symptoms, and 0 to 63 for new or worse symptoms, still scored 10–20 for persistent symptoms in the patient. The patient also encountered a rapid increase in the anti-PR3 titer eight months after discontinuation of trastuzumab (Table 2). Recent evidence has supported neutrophil as the dominant infiltrate within vasculitis lesions [12–14]. And the discovery of neutrophil extracellular traps (NETs), a component of cell-free DNA, histone, proteinase 3 (PR3), and myeloperoxidase (MPO) released by ANCA-stimulated neutrophil, could induce vasculitis damage such as thrombus formation and endothelial damage. The patient was enrolled in a prospective vasculitis cohort in our facility for testing on vasculitis neutrophil-derived NETs and had also started rituximab (500 mg D1/D15, every 6 months) therapy for better control for the DIILD.

2. Prospective cohort on neutrophil derived biomarkers in vasculitis disease activity

2.1. Materials and methods

From 2017 to 2021, a prospective cohort study addressing neutrophil related biomarkers in the evaluation of patients with vasculitis was initiated in our facility (Suppl. Fig. S1). The aim was to explore the relationship between levels of cell-free MPO-DNA, a biomarker for NEtosis and the clinical activity of systemic vasculitis. Including the Case presented in the manuscript, a total of eight patients with vasculitis and 17 healthy controls (a ratio of 1:2) were enrolled, and serial serum testing was obtained (Suppl. Fig. S2). The study was approved by the hospital Institutional Review Board in 2017 (NTUH: 201612147RINA). Informed consents were obtained from all patients and healthy donors.
2.2. Measurement of MPO-DNA and ANCA

We tested each vasculitis individual for the cell-free MPO-DNA via a "sandwich" ELISA with an anti-MPO polyclonal antibody (GeneTex, GTX22088, Irvine, Ca, USA). ELISA microplates were coated with the MPO monoclonal antibody overnight to capture MPO-associated DNAs. Anti-ds DNA-specific monoclonal antibodies (Abcam, Cambridge, ab27156, UK; 1:2000) were added to bind MPO-associated DNA, followed by binding of a horseradish peroxidase-conjugated anti-mouse IgG antibody (Jackson ImmunoResearch, 115-035-003) for detection. A peroxidase substrate (3,3',5,5'-Tetramethylbenzidine) was added to react with the

Fig. 1. A-D. (A) Chest radiograph (CXR) at initial presentation revealed multi-lobar consolidation with a centi-hilar pattern. (B) CXR on the third day showed rapid bilateral pulmonary infiltrate progression (C–D) Computed tomography (CT) on the third day showed a diffuse, multi-lobar consolidation with a peri-bronchovascular pattern.

Fig. 2. A-B Bronchoscopy examination of the tracheal (A) and main carina (B) revealed fresh blood in the whole airway without active vascular bleeding.
conjugated peroxidase to yield a blue product. The reaction was halted by adding 2 N H₂SO₄, and the absorbance of the final product was measured at 450 nm and was transformed to an arbitrary unit (a.u.) according to the previous study [15]. An MPO-DNA assay standard curve is provided (Suppl. Fig. S3).

ANCA assessment was performed using anti-proteinase (PR3) and anti-myeloperoxidase (MPO) specific immunoassays (EliA; Thermo Fisher Scientific, Waltham, MA, USA). The assay was performed according to the manufacturer’s instructions. An antibody concentration was considered positive if: MPO > 5.0 IU/mL and PR3

![Figure 3](image)

**Fig. 3.** A Lung, left upper lobe, wedge resection, low power field (100X), interstitial fibrosis with collagen deposits (C) and alveolar airspace obliteration (A). B High power field showing alveolar hemorrhage (A), and necrotic neutrophils (P) in a capillary wall (V) and alveoli. C Comparison of the patient sample to a sample from a healthy individual shows marked airspace obliteration due to hemorrhage and interstitial thickening.

**Table 1**
Probable Trastuzumab related adverse drug reaction, with Naranjo score of 7 according to the patients clinical history.

| No | Question                                                   | Yes | No | Do Not Know |
|----|------------------------------------------------------------|-----|----|-------------|
| I  | Are there previous conclusive reports on this reaction?   | +1  | 0  | 0           |
| II | Did the adverse event appear after the suspected drug was administered? | +2  | −1 | 0           |
| III| Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered? | +1  | 0  | 0           |
| VI | Did the adverse reaction reappear when the drug was administered? | +2  | −1 | 0           |
| V  | Are there alternative causes (other than the drug) that could on their own have caused the reaction? | −1  | +2 | 0           |
| VI | Did the reaction reappear when a placebo was given?       | −1  | +1 | 0           |
| VII| Was the drug detected in the blood (or other fluids) in concentration known to be toxic? | +1  | 0  | 0           |
| VIII| Was the reaction more severe when the dose was increased or less severe when the dose was decreased? | +1  | 0  | 0           |
| IX | Did the patient have a similar reaction to the same or similar drugs in any previous exposure? | +1  | 0  | 0           |
| X  | Was the adverse event confirmed by any objective evidence? | +1  | 0  | 0           |

Naranjo score for estimating the probability of adverse drug reactions; 0, doubtful ADR; 1–4 possible ADR; 5–8, probable ADR; ≥9 definite ADR.
3.0 IU/mL (normal range were provided by the manufacturer).

2.3. Statistical analysis

We utilized Stata statistical software (V. 14.0, Stata Corporation, College Station, TX) for the analysis. The MPO-DNA cut-off point between healthy controls and vasculitis patients was obtained according to the maximum Youden index (Sensitivity + Specificity - 1) to capture the performance of this dichotomous diagnostic test [16]. Statistical significance of the difference between two sets of continuous variables was analyzed using a Mann-Whitney U test. A p-value less than 0.05 was defined as statistically significant.

3. Results

3.1. MPO DNA performance in the prospective vasculitis cohort

The MPO-DNA values were significantly higher in the systemic vasculitis group (n = 8; 0.092 ± 0.071 arbitrary unit (a.u.)) relative to healthy donors (n = 17; 0.015 ± 0.018 a.u., p = 0.01) (Table 3). The Youden J index representing the maximum potential effectiveness of the upper-lower limit of the MPO-DNA cut-off value was 0.047 (a.u.), the red dashed line (Table 3). An MPO-DNA cut-off level at = 0.047 a.u. was established to differentiate between healthy control and vasculitis patients. We also tested MPO-DNA serum level, erythrocyte sedimentation rate, C-reactive protein correlation with their Birmingham Vasculitis Activity Score. The MPO-DNA showed a moderate positive correlation [ r (n = 12) = 0.596, p = 0.025]; but the C-reactive protein [ r (n = 10) = 0.402, p = 0.196] and the erythrocyte sedimentation rate [ r (n = 9) = 0.119, p = 0.727] showed no correlation with clinical vasculitis severity. These results suggest that MPO-DNA levels may also be useful in monitoring vasculitis activity compared to standard inflammation biomarkers (Table 4).

3.2. MPO DNA performance in the trastuzumab ILD case

During follow-up of the Case presenting trastuzumab-induced...
ILD, we found that despite standard vasculitis anti-PR3 is capable of showing good correlation during initial glucocorticoid therapy with the Birmingham vasculitis score (BVAS). The correlation was lost after salvage treatment with the B-cell targeting agent rituximab was initiated (Table 2). MPO-DNA levels exhibited a better correlation with the clinical vasculitis activity BVAS score during the rituximab treatment period.

4. Discussion

Interstitial lung disease (ILD) induced by HER2-targeted agents is a well-known adverse drug reaction, but the mechanism is ill-defined and considered low in incidence [17]. HER-2 targeted agents such as trastuzumab, trastuzumab emtansine had been reported to induce cutaneous vasculitis in the previous literature [18–20], but pulmonary vasculitis due to HER2 targeted agents had not been reported yet.

A recent review of 9886 patients investigating anti-HER2 therapies for HER2 breast cancer had reported the overall incidence of ILD was 2.4%. The incidence of grade 1–2, grade 3–4, and grade 5 events were 66.7%, 23.0%, and 0.2% respectively. The agents leading to the highest ILD incidence was trastuzumab combined with everolimus or paclitaxel. The incidence of ILD-related deaths was highest among patients receiving trastuzumab deruxtecan (T-Dxd), with an incidence of around 2% [17]. Recently the oncology society has drawn attention to this adverse event due to the recent accelerated approval of T-Dxd [9,21]. The novel antibody-drug conjugate had shown a 60% response rate in third or later line metastatic HER-2 positive breast cancer but at the cost of treatment-related ILD up to 13% and 2% treatment-related death. This high rate of side effects will inhibit its potential to be utilized as the frontline therapy or even be placed in the curative adjuvant or neoadjuvant setting.

Table 3

| MPO-DNA values were significantly higher in the systemic vasculitis group [n = 8; 0.092 ± 0.071 arbitrary units (A.U.)] relative to healthy donors [n = 17; 0.015 ± 0.018 A.U., p = 0.01]. Youden J index representing the maximum potential effectiveness of the upper-lower limit of the MPO-DNA cut-off value, which was set at 0.047 (A.U.), as indicated by the red dashed line. | MPO-DNA (arbitrary unit [A.U.]) |

Table 4

| The MPO-DNA serum levels, erythrocyte sedimentation rates, and C-reactive protein correlation with the Birmingham Vasculitis Activity Score for the eight vasculitis patients, the MPO-DNA showed a moderate positive correlation but the C-reactive protein and erythrocyte sedimentation rate did not. | MPO-DNA v BVAS Score | ESR v BVAS Score | CRP v BVAS Score |
A recently published article by Kumagai et al. had reported successful induction of T-Dxd interstitial lung disease in a cynomolgus monkey model. Receiving T-Dxd in a monkey model developed interstitial lung disease, whereas receiving Dxd does not. Although most ILD lesions were found within the alveoli, the HER2 expression in lungs was limited to the bronchial level [22]. Vasculitis due to a pathway via ANCA autoantibodies, an indirect mechanism by the immune system, could explain why the injury was not at the location where T-Dxd was uptaken. Moreover, a two-step mechanism of pathogenesis explains how DILD (drug-induced ILD) manifests later after anti-SNL-2 therapies. A literature review was performed to summarize previously reported cases of trastuzumab-related ILD. A total of 8 cases were identified before our Case [23–28]. Two of the reported cases had available pathology that showed organizing pneumonia or diffuse alveolar damage. No traceable serum marker was reported in previously reported patients. All previously reported cases that we identified had late onset with a median time of onset two months after the first trastuzumab exposure (Table 5). The pattern of CT infiltration largely comprised ground-glass opacity and patch consolidations, with only one case exhibiting nodular lesions. Most patients recovered following prednisolone-based monotherapy, and only one patient died. Long-term follow up was not conducted in these cases. Our case also had a protracted course of vasculitis up to two years. We found that both ANCA auto-antibody testing and NET related biomarker, MPO-DNA should be tested concomitantly and only a biopsy cannot be immediately obtained. Pre-treatment targeted therapy induces pulmonary ILD via ANCA autoantibodies. Early suspicion with testing of ANCA level can be life-saving when a biopsy cannot be immediately obtained. Pre-treatment ANCA level testing may also be considered in the future when treating patients with HER-2 agents with higher risk profiles of ILD. In addition, serum MPO-DNA, could be a biomarker with promising clinical implication, as the results from this case and a prospective vasculitis cohort in our facility indicated.

**Authors’ contribution**

C.H.C., Y.M.H., and Y.M.K., wrote the original draft writing with input from all authors; Y.M.K., C.J.J., designed, developed and conducted the experiments; Y.M.K., L.C., are the primary physicians responsible for the patient medical treatment; Y.L.C., reviews the surgical pathology and issues the report.; S.C.H., Y.M.H., C.H.L., contributed to the final version of the manuscript; All authors actively participated in the discussion and suggestion for the manuscript.

**Funding**

This article was subsidized for English editing by National
Taiwan University under the Excellence Improvement Program for Doctoral Students (grant number 108-2926-I-002-002-MY4), sponsored by the Ministry of Science and Technology, Taiwan. This work was supported by Ministry of Science and Technology (MOST 108-2314-B-002-097-MY3, 107-2314-B-025-106, 2314-B-002-100), National Taiwan University Hospital (NTUH 110-M4972) and Taiwan Rheumatology Association Research Fund (TRARF-2018).

Ethics approval

This study was approved by the hospital Institutional Review Board (NTUH: 201612147RINA). The informed consent was obtained from the patients.

Availability of data and material

The author(s) confirm that the data supporting the findings of this study are available within the article.

Code availability

The author(s) confirm that the data supporting the findings of this study are available within the article.

Declaration of competing interest

The author(s) declared that no conflicts of interest exist.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.breast.2021.11.016.

References

[1] Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007;357(1):39–51. https://doi.org/10.1056/NEJma043186.
[2] Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355(26):2733–43. https://doi.org/10.1056/NEJMoa064320.
[3] Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011;12(3):236–44. https://doi.org/10.1016/S1470-2045(11)70033-X.
[4] Verma S, Miles D, Gianni L, Krop IE, Welslau M, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367(19):1783–91. https://doi.org/10.1056/NEJma1209124.
[5] Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, et al. Drug-induced intestinal lung disease: a systematic review. J Clin Med 2018;7(10). https://doi.org/10.3390/jcm7100156.
[6] Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659–72. https://doi.org/10.1056/NEJMoa052306.
[7] Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2020;183(1):9–19.
[8] Wong M, Grossman J, Hahn BH, La Cava A. Cutaneous vasculitis in breast cancer treated with chemotherapy. Clin Immunol 2008;129(1–3):9–19. https://doi.org/10.1016/j.clim.2008.07.001.
[9] Bhardwaj AS, Mclellan B, Robinson MR, Chow O, Lipsy LR, et al. A Case of vasculitis in a breast cancer patient treated with T-DM1. Semin Oncol 2014;41(3). https://doi.org/10.1053/j.seminoncol.2014.08.010, e95–45.
[10] Suzuki Y, Yokida Y, Saito Y, Ohta M, Tajima T. Combination of trastuzumab and vinorelbine in metastatic breast cancer. Jpn J Clin Oncol 2003;33(10):514–7. https://doi.org/10.1093/jjco/hyg101.
[11] Anders CR, LeBoeuf NR, Bashoura L, Faiz SA, Shariff AF, et al. What’s the price? Toxicities of targeted therapies in breast cancer care, vol. 40. American Society of Clinical Oncology Educational Book; 2020. p. 55–70. https://doi.org/10.1200/edbk_279465.
[12] Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2020;183(1):9–19.
[13] Csernok E, Hellmich B. Usefulness of vasculitis biomarkers in the era of the personalized medicine. Autoimmun Rev 2020;19(5):102514. https://doi.org/10.1016/j.autrev.2020.102514.
[14] Almaani S, Fussner LA, Brodsky S, Patel S, Pateinas P, et al. Angiotensin II triggers neutrophil extracellular traps release linking thrombomodulation with essential hypertension. J Cell Insight 2021. https://doi.org/10.1172/jci.insight.148668.
[15] Chrysanthenopoulou A, Gkaliagkousi E, Lazaridis A, Arelakis S, Pateinas P, et al. Modification and validation of the Birmingham vasculitis activity score (version 3). Ann Rheum Dis 2009;68(12):1827–32. https://doi.org/10.1136/ard.2008.101279.